Handgrip strength asymmetry as a new biomarker for sarcopenia and individual sarcopenia signatures.
Biomarkers
Maximal strength
Sarcopenia
Screening
Strength asymmetry
Journal
Aging clinical and experimental research
ISSN: 1720-8319
Titre abrégé: Aging Clin Exp Res
Pays: Germany
ID NLM: 101132995
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
15
05
2023
accepted:
16
08
2023
medline:
8
11
2023
pubmed:
4
9
2023
entrez:
2
9
2023
Statut:
ppublish
Résumé
Although handgrip strength (HGS) asymmetry has clinical screening utility, its relevance to sarcopenia is unknown. This study examined the relationship between HGS asymmetry and sarcopenia signatures, and explored the relevance of circulating neural/neuromuscular markers. 9403 individuals aged 18-92 years participated in this study. Maximal HGS and skeletal muscle index (SMI) were determined using hand dynamometry and DXA. Sarcopenia was diagnosed upon the presence of low HGS and low SMI, according to cohort-specific thresholds. Plasma biomarkers were measured by ELISA in a sub-group of 269 participants aged 50-83 years. Asymmetry was determined as the highest recorded HGS divided by the highest recorded HGS of the opposite hand. Individuals with a ratio > 1.10 were classified as having asymmetrical HGS. Subjects with asymmetrical HGS had significantly lower SMI (7.67 kg/m Our findings demonstrate the utility of HGS asymmetry as a screening tool that may complement existing strategies seeking to combat sarcopenia. Biomarker analyses suggest that heightened denervation may be an important aetiological factor underpinning HGS asymmetry.
Sections du résumé
BACKGROUND
BACKGROUND
Although handgrip strength (HGS) asymmetry has clinical screening utility, its relevance to sarcopenia is unknown. This study examined the relationship between HGS asymmetry and sarcopenia signatures, and explored the relevance of circulating neural/neuromuscular markers.
METHODS
METHODS
9403 individuals aged 18-92 years participated in this study. Maximal HGS and skeletal muscle index (SMI) were determined using hand dynamometry and DXA. Sarcopenia was diagnosed upon the presence of low HGS and low SMI, according to cohort-specific thresholds. Plasma biomarkers were measured by ELISA in a sub-group of 269 participants aged 50-83 years. Asymmetry was determined as the highest recorded HGS divided by the highest recorded HGS of the opposite hand. Individuals with a ratio > 1.10 were classified as having asymmetrical HGS.
RESULTS
RESULTS
Subjects with asymmetrical HGS had significantly lower SMI (7.67 kg/m
DISCUSSION
CONCLUSIONS
Our findings demonstrate the utility of HGS asymmetry as a screening tool that may complement existing strategies seeking to combat sarcopenia. Biomarker analyses suggest that heightened denervation may be an important aetiological factor underpinning HGS asymmetry.
Identifiants
pubmed: 37658983
doi: 10.1007/s40520-023-02539-z
pii: 10.1007/s40520-023-02539-z
pmc: PMC10627945
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2563-2571Informations de copyright
© 2023. The Author(s).
Références
J Gerontol A Biol Sci Med Sci. 2003 Feb;58(2):146-52
pubmed: 12586852
J Gerontol A Biol Sci Med Sci. 2021 Nov 15;76(12):2090-2096
pubmed: 33993303
J Gerontol A Biol Sci Med Sci. 2021 Jan 18;76(2):291-296
pubmed: 32319511
Aging Clin Exp Res. 2021 Sep;33(9):2461-2469
pubmed: 33247424
Geroscience. 2021 Oct;43(5):2533-2546
pubmed: 34213693
Aust J Physiother. 2005;51(2):119-22
pubmed: 15924514
Sci Rep. 2019 Jan 24;9(1):584
pubmed: 30679750
Neuroimage. 2003 Jul;19(3):913-23
pubmed: 12880820
Nat Rev Neurol. 2018 Oct;14(10):577-589
pubmed: 30171200
PLoS One. 2006 Dec 20;1:e90
pubmed: 17183722
J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1514-1525
pubmed: 35445560
J Neurol Sci. 2019 Jan 15;396:36-41
pubmed: 30412901
Sports Med. 2016 Sep;46(9):1311-32
pubmed: 26893098
Geroscience. 2023 Jun;45(3):1289-1302
pubmed: 36609795
Age Ageing. 2011 Jul;40(4):423-9
pubmed: 21624928
Percept Mot Skills. 2003 Jun;96(3 Pt 1):728-30
pubmed: 12831245
J Sports Sci. 2010 Apr;28(6):667-77
pubmed: 20397097
Neuroimage. 2007 Jan 1;34(1):274-80
pubmed: 17056278
Arch Gerontol Geriatr. 2022 Sep-Oct;102:104716
pubmed: 35569287
J Am Med Dir Assoc. 2017 Jun 1;18(6):551.e17-551.e35
pubmed: 28549705
Clin Chem Lab Med. 2016 Oct 1;54(10):1655-61
pubmed: 27071153
J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1811-1820
pubmed: 35415973
Med Sci Sports Exerc. 2012 Nov;44(11):2172-81
pubmed: 22617401
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Neurobiol Aging. 2018 Nov;71:189-222
pubmed: 30172220
Exp Brain Res. 2007 Sep;182(2):275-9
pubmed: 17717653
Br J Gen Pract. 2016 Jun;66(647):331-2
pubmed: 27231304
PLoS One. 2014 Apr 02;9(4):e93892
pubmed: 24695543
BMC Geriatr. 2017 Oct 16;17(1):238
pubmed: 29037155
J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):325-332
pubmed: 34953058
Age (Dordr). 2013 Jun;35(3):929-41
pubmed: 22314403
Neuroimage. 1996 Dec;4(3 Pt 1):216-22
pubmed: 9345512
BMC Geriatr. 2018 Apr 13;18(1):90
pubmed: 29653515
J Musculoskelet Neuronal Interact. 2013 Sep;13(3):320-8
pubmed: 23989253
J Diabetes Metab Disord. 2017 May 16;16:21
pubmed: 28523252
J Gerontol A Biol Sci Med Sci. 2015 Sep;70(9):1112-9
pubmed: 25834195
FASEB J. 2008 Jun;22(6):1861-73
pubmed: 18230682
J Am Geriatr Soc. 2020 Jul;68(7):1429-1437
pubmed: 32633824
J Cachexia Sarcopenia Muscle. 2022 Apr;13(2):1013-1023
pubmed: 35178892